Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

by Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu, Yuhua Li
Published 2020-05-01

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

by Sanfang Tu, Xuan Zhou, Zhenling Guo, Rui Huang, Chunyan Yue, Yanjie He, Meifang Li, Yiran Chen, YuChen Liu, Lung-ji Chang, Lung-ji Chang, Lung-ji Chang, Yuhua Li
Published 2019-12-01

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

by Xuan Zhou, Sanfang Tu, Chunsheng Wang, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Zhao Liang, Anqin Wu, Meifang Li, Weijun Zhou, Jingwen Du, Zhenling Guo, Yongqian Li, Cheng Jiao, Yuchen Liu, Lung-Ji Chang, Lung-Ji Chang, Yuhua Li, Yuhua Li
Published 2020-11-01